Clinical Trials

Rectal Neoplasms

NCT04920032 2026-04-13

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Phase 1 Recruiting

22 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

Phase 1/2 Recruiting

45 enrolled

Metastatic Gastric Adenocarcinoma

NCT05854498 2026-04-02

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

NCT07011550 2026-03-20

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

Phase 2 Suspended

7 enrolled

Microsatellite-stable Colorectal Cancer

NCT05806931 2026-03-18

SCOTI

Colonic Neoplasms, Rectal Neoplasms

NCT03223779 2026-03-12

Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer

Phase 1/2 Completed

52 enrolled

Colorectal Neoplasms

NCT05343013 2026-03-06

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

25 enrolled

Colorectal Neoplasms

NCT03686488 2026-03-02

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

23 enrolled 12 charts

Stomach Neoplasms

NCT04511039 2026-03-02

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Phase 1 Recruiting

45 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Colorectal Neoplasms

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

100 enrolled

Colorectal Neoplasms

NCT07146646 2026-02-19

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

27 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04109924 2026-02-10

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

42 enrolled 12 charts

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07270991 2026-02-05

FRUQUITAS

Phase 3 Recruiting

324 enrolled

Tumor-Agnostic

Neoplasms

NCT05062889 2026-02-03

ERASE-CRC

Phase 2 Suspended

477 enrolled

Phase 2 Not yet recruiting

Colonic Neoplasms

NCT07381764 2026-02-02

ROMANCE - GOIM

150 enrolled

Phase NA Not yet recruiting

Colorectal Neoplasms

NCT07371871 2026-01-28

A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer

30 enrolled

Advanced Gastric Cancer

NCT04457297 2026-01-21

ALTAIR

Phase 3 Completed

243 enrolled 13 charts

Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Colorectal Neoplasms

NCT03844620 2026-01-09

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

100 enrolled

Colorectal Neoplasms

NCT04564898 2026-01-08

TriComB

48 enrolled

Colorectal Cancer Metastatic

NCT06856837 2025-12-12

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

140 enrolled

Colorectal Neoplasms

NCT04417699 2025-12-10

SHORT

13 enrolled 12 charts

Rectal Neoplasms

NCT06245356 2025-12-10

TRIFLUOX-DP

73 enrolled

Colorectal Neoplasms, Dihydropyrimidine Dehydrogenase Deficiency

NCT04042714 2025-11-04

TAS-102 NEC

Phase 2 Terminated

14 enrolled

Endocrine

High-grade Extra Pulmonary Neuroendocrine Cancer

NCT07212933 2025-10-08

RAK in GC

90 enrolled

Phase 1/2 Not yet recruiting

Stomach Neoplasms

NCT07196345 2025-09-29

TAS-102 Plus Radiotherapy in Elderly ESCC

45 enrolled

ESCC

NCT04280536 2025-09-23

Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA)

86 enrolled

Breast

Breast Neoplasms

NCT06887218 2025-08-27

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

57 enrolled

Colorectal Neoplasms

NCT07142421 2025-08-26

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

35 enrolled

Esophageal Squamous Cell Carcinoma

NCT07138885 2025-08-24

DRIVE-II

62 enrolled

Carcinoma, Hepatocellular

NCT04166604 2025-08-19

LONGBOARD

176 enrolled

Phase 2 Not yet recruiting

Neutropenia, Colorectal Neoplasms

NCT07116577 2025-08-11

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

37 enrolled

mCRC

NCT07090031 2025-07-29

Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer

49 enrolled

EFS

NCT07085169 2025-07-25

Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC

Colonic Neoplasms

NCT04923529 2025-07-18

TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma

28 enrolled

Phase 2 Not yet recruiting

Pancreatic Neoplasms

NCT07071844 2025-07-17

BETWEEN

162 enrolled

Neutropenia, Colorectal Neoplasms

NCT05508737 2025-07-11

Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer

75 enrolled

Phase 3 Not yet recruiting

Gastric and Gastroesophageal Junction Adenocarcinoma

NCT06850090 2025-06-25

Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial

210 enrolled

Rectal Neoplasms

NCT07012954 2025-06-24

ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

Phase 1/2 Recruiting

64 enrolled

Colorectal Cancer Metastatic

NCT05481463 2025-05-28

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

22 enrolled

Pancreatic Neoplasms

NCT05965531 2025-04-29

TASLARC

65 enrolled

Phase 1 Active not recruiting

Rectal Neoplasms

NCT04868773 2025-04-16

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

12 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT04450836 2025-03-30

SOREGATT

Phase 2 Terminated

234 enrolled

Phase 1 Not yet recruiting

Colorectal Neoplasms

NCT06882915 2025-03-19

Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study

20 enrolled

Colorectal Neoplasms

NCT03368963 2025-01-07

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

64 enrolled

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04260269 2024-12-12

CardioSwitch

Enrolling by invitation

200 enrolled

Other solid neoplasm

Solid Tumor

NCT06711471 2024-12-02

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

31 enrolled

Gastric Cancer Adenocarcinoma Metastatic

NCT04294264 2024-11-18

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

Colonic Neoplasms, Colorectal Neoplasms

NCT05476796 2024-10-24

LOGICAN

118 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Neoplasm Metastasis, Recurrence

NCT06403709 2024-09-24

Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients

35 enrolled